当前位置: X-MOL 学术Nat. Rev. Drug. Disc. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
John-Arne Røttingen.
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2020-05-01 , DOI: 10.1038/d41573-020-00072-6
Asher Mullard

Over 180 clinical trials of proposed COVID-19 drugs are already recruiting patients, and another 150 are registered to start recruiting patients soon. But many of these trials are small and not designed to identify the best treatment strategies for the COVID-19 pandemic. For Chief Executive of the Research Council of Norway John-Arne Røttingen, a more collaborative approach is now needed. And as Chair of the Executive Group and the International Steering Committee of the WHO’s recently launched Solidarity trial, he hopes this mega-trial can provide a blueprint, he told Asher Mullard.

中文翻译:

John-ArneRø​​ttingen。

提议的COVID-19药物的180多项临床试验已经在招募患者,另有150项已注册以开始招募患者。但是,这些试验中有许多试验规模较小,并且并非旨在确定COVID-19大流行的最佳治疗策略。对于挪威研究委员会首席执行官约翰·阿恩·罗廷根(John-ArneRø​​ttingen),现在需要一种更具协作性的方法。他告诉世贸组织阿舍·穆拉德(Azer Mullard),作为世卫组织最近启动的团结试验的执行小组主席和国际指导委员会主席,他希望这一大型试验能够提供一个蓝图。
更新日期:2020-04-14
down
wechat
bug